Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough Clarinex NDA Approval Awaits Resolution Of GMP Problems

Executive Summary

Schering-Plough's Clarinex (desloratadine) NDA will not be approved until the company answers FDA concerns regarding Good Manufacturing Practices compliance at a wide range of Schering operations.
Advertisement

Related Content

Schering Clarinex Approval Comes In Time For Big Spring Push
PEG-Intron Access Program Requires ID Number, Designed To Ensure Supply
Schering Reinspection Brings New FDA-483s: Firm Updates Compliance Plans
Schering Desloratadine Onset Of Action Is 1-2 Hours - EU Review Document
Zyprexa IM Manufacturing Issues To Be Discussed By FDA, Lilly March 15
Aventis Allegra Once-Daily New Prescription Market Share Reaches 13%
Claritin Supply Sufficient For Spring, Schering Says; FDA Lists GMP Problems
GlaxoSmithKline Is Mouthful But Still Hungry: Is Next Course Japanese?
Schering Implementing Four-Phase Proposal For Proventil Batch Release
Schering Implementing Four-Phase Proposal For Proventil Batch Release
Advertisement
UsernamePublicRestriction

Register

PS037376

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel